Clinical Trials

  • Principal Investigator:

    Sahil A. Parikh, MD
    The objective of the LIFE-BTK RCT is to evaluate the safety and efficacy of the ESPRIT BTK device (which is a bioresorbable polymeric scaffold with the everolimus drug and a bioresorbable polymeric coating mounted on a balloon dilatation catheter) compared to Percutaneous Transluminal Angioplasty (PTA), which is is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a "balloon" at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow can be restored. The balloon is then...
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    This is a research study for patients who have Tricuspid Regurgitation (TR), a condition that occurs when the three leaflets of the hearts tricuspid valve do not close properly causing blood to leak backward with each heartbeat. Since some of the blood leaks backward, the heart has to pump more blood with each beat to push the same amount of blood forward. The goal of this study is to evaluate the safety and performance of the EVOQUE Valve in patients with at least moderate tricuspid regurgitation and signs of, symptoms from or prior heart failure hospitalizations for tricuspid regurgitation...
  • Principal Investigator:

    Jeffrey W Moses, MD
    The purpose of this research study is to evaluate if it is safe and feasible to use the Impella Hemodynamic Platform to measure and display hemodynamic parameters (measurements of how much pressure the heart is generating and how much blood your heart is pumping) during PCI procedures. PCI is a surgical procedure that uses a catheter (a thin flexible tube) to place a small structure called a stent to open up blood vessels in the heart that have been narrowed by plaque buildup. The Impella device will be placed via the a femoral artery and delivers up to 3.5 liters of blood per minute to the...
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    This study is designed to look at the safety and performance of The Intrepid TMVR System using transfemoral transseptal access (TF). TF is a procedure that requires access to the femoral vein by an incision in the lower limb between the knee and the hip. The study population is for patients with severe, symptomatic mitral regurgitation (MR), a condition where the blood draws back into the mitral valve causing the heart to pump harder. The population of patients are also those who are not eligible for conventional mitral valve surgery. For participants in this study population, the doctors...
  • Principal Investigator:

    Marwah Abdalla, MD, MPH
    The Center for Behavioral Cardiovascular Health (CBCH) is conducting a research study to examine the relationship between sleep and nighttime blood pressure levels and whether this relationship has something to do with the way our nervous system functions. Qualified participants who complete a 2 day study that includes an overnight sleep assessment at the Columbia University Cardiopulmonary Sleep and Ventilation Disorders Center are eligible for a $200 compensation.
  • Principal Investigator:

    Tamim M. Nazif, MD
    This is a prospective, single-arm, observational, multicenter registry. The intent is to gather information on the commercially approved device, device SAPIEN 3 Ultra transcatheter heart valve (THV). This valve consists of a short metal tube (stent) that holds the valve in its intended position and has valve leaflets made of biological material derived from cows to direct the flow of blood through the heart the way a normal valve would if it was healthy. This artificial valve is delivered into the heart by a small flexible tube (catheter) that is about as big around as a pencil. This flexible...
  • Principal Investigator:

    Amardeep S. Saluja, MD
    The primary objective of the TactiFlex PAF IDE clinical trial is to demonstrate that ablation with the TactiFlex Ablation Catheter, Sensor-Enabled (TactiFlex SE), in conjunction with a compatible RF generator and three-dimensional mapping system, is safe and effective for the treatment of drug refractory, symptomatic paroxysmal atrial fibrillation (PAF) when following standard electrophysiology mapping and radiofrequency (RF) ablation procedures. The study is a prospective, non-randomized multi-center clinical investigation. The design includes a main study and a separate substudy. Subjects...
  • Principal Investigator:

    Sahil A. Parikh, MD
    This study is to test if a combination drug/device therapy using TEMSIROLIMUS (Temsirolimus Injection), with or without the generic steroid DEXAMETHASONE (Dexamethasone Sodium Phosphate Injection), can be delivered safely into the tissue around the blood vessel wall at the time of an angioplasty ( which is a a procedure to open blocked arteries and restore blood flow) and whether that delivery helps to prevent re-narrowing of the blood vessel. If you are 18 and have a narrowing or blockage of the blood vessels (arteries) in your leg which your physician has determined needs to be treated with...
  • Principal Investigator:

    Nir Uriel, MD, MSc
    The purpose of this research study is to understand if aspirin is needed in patients heart failure implanted with the HeartMate 3. Patients with devices like the HeartMate 3 take two blood thinner medicines, specifically warfarin and aspirin. Patients implanted with devices like the HeartMate 3 experience both clotting and bleeding complications. Data suggest the HeartMate 3 may not require as much anticoagulation (blood thinners) as are normally used. This study will test if patients need aspirin together with warfarin or just warfarin alone.
  • Principal Investigator:

    Daichi Shimbo, MD
    We are conducting a research study in adults to test whether blood pressure (BP) measured in a clinic setting without a technician present is comparable to blood pressure levels while awake outside of the clinic on an Ambulatory Blood Pressure Monitoring (ABPM) device. We will also test whether asleep blood pressure can be accurately determined using a home blood pressure monitoring device, called HBPM. Eligible participants include English or Spanish-speaking adults who don't have cardiovascular disease and are NOT currently taking a blood pressure lowering medication. Study participation...

Pages